This bill protects small biotech companies from having their drug prices negotiated by Medicare, encouraging them to invest in research and development. It aims to support innovation in the biotech industry.
If you rely on new biotech drugs, this bill could help ensure those companies keep innovating without price pressure.
Who this affects
Small biotech manufacturers
What changes is this bill making?
1This bill creates an exception for small biotech manufacturers in drug price negotiations.
2It allows these manufacturers to avoid price negotiations if they meet certain criteria.
3The bill defines a small biotech manufacturer based on the number of qualifying drugs they have.
4It requires these manufacturers to invest a specific percentage of their revenue in research and development.
5The exception applies starting in 2029 for qualifying drugs.
